Deep Intelligent Pharma and China National Medicines Corporation Forge Comprehensive Strategic Partnership to Pioneer AI-Driven Drug Discovery
Recently, Deep Intelligence Pharma (DIP), a Chinese AI-driven drug R&D enterprise, signed a comprehensive strategic cooperation agreement with China National Pharmaceutical Group Corporation. The two parties will collaborate across multiple domains, including AI-powered innovative drug design and screening, knowledge graphs, AI-assisted drug synthesis, AI-enabled clinical trials, AI-based translation, AI-driven pharmaceutical manufacturing, AI-supported regulatory submission, and intelligent regulation. Furthermore, this partnership will leverage DIP’s small-molecule drug discovery platform, built on robust artificial intelligence technologies, to develop global innovative drugs targeting multiple therapeutic targets.
China’s “4+7” Volume-Based Procurement (VBP) program has accelerated the transformation of domestic generic drug manufacturers into innovative pharmaceutical enterprises, ushering in a rare historical opportunity for innovative drugs in China. In a landmark move, a Chinese AI-driven drug discovery company has joined forces with a state-owned enterprise for the first time. This strategic alliance between two industry leaders aims to co-develop an integrated intelligent R&D pipeline, empowering pharmaceutical companies globally—particularly in China—to accelerate growth during this period of profound industrial transformation. Deep Intelligence will leverage its strengths in applying artificial intelligence to empower the entire process of new drug R&D, manufacturing, and regulatory submission, while China National Pharmaceutical Group Corporation (Sinopharm) will contribute its advantages in capital, equipment, and market access. Together, they will comprehensively advance R&D collaboration and achieve deep integration of technological innovation.
High-throughput screening and traditional virtual drug screening are time-consuming and associated with low success rates in drug development. The emergence of artificial intelligence (AI) has opened new avenues for the discovery of innovative small-molecule drugs. DeepIntellect’s AI-powered early-stage drug discovery platform can identify 10–100 lead compounds from target discovery within just 7 to 30 days, significantly enhancing efficiency. The platform has collaborated with more than 20 pharmaceutical companies and research institutes both in China and abroad, achieving numerous successful cases.
Meanwhile, Deep Intelligence leverages its De novo platform (designing drugs from scratch) to selectively construct a novel library of druggable compounds, reaching an order of magnitude of 10.20~1025...greatly expanding the searchable chemical space and reaching frontiers inaccessible to human experts. AI-driven drug discovery will help pharmaceutical companies significantly reduce R&D costs, accelerate time-to-market, and improve success rates.
logP: lipid-water partition coefficient; MW: molecular weight; MCFs: Medicinal Chemistry Filters; VAS: virtual screening; CPI: compound-protein interaction; ADMET: absorption, distribution, metabolism, excretion, and toxicity; *Using a de novo designed molecular library; **Synthetic accessibility filtering is required only when screening AI-generated databases.
China National Pharmaceutical Industry Corporation Limited is a state-controlled listed company listed on the Shanghai Stock Exchange. The Company has established an integrated industrial pattern combining science, industry, and trade, led by international trade, supported by pharmaceutical manufacturing, and linked by pharmaceutical commerce. Its business operations cover the entire industry chain, including R&D, cultivation and processing, production, distribution, logistics, import and export trade, academic promotion, and technical services. The Company possesses a domestically leading R&D and production platform for chemical active pharmaceutical ingredients (APIs), as well as advanced domestic platforms for the R&D and production of specialized chemical drugs and modern traditional Chinese medicines. It holds a leading position in the R&D and production of anti-infective and antiviral drugs, as well as in the cultivation and processing of medicinal herbs such as licorice root and their related products.
Deep Intelligence is committed to leveraging artificial intelligence technologies to empower the entire new drug development process on a global scale. In the early stages of drug discovery, its AI-powered knowledge graph (Di-GraPhMed™), AI-driven small-molecule drug discovery platform (Di-DrugGOES™), and drug synthesis platform (ChemSynther™) provide pharmaceutical companies and research institutions with comprehensive solutions spanning project feasibility studies, small-molecule drug design, drug repurposing, and biomarker discovery and validation.
Meanwhile, DeepBioscience’s self-developed AI intelligent systems and related services span clinical research, pharmacovigilance, regulatory submissions, and medical translation. The company currently serves nearly 190 global pharmaceutical companies worldwide, including established multinational corporations such as Bayer and Merck & Co., as well as international innovative biopharmaceutical enterprises like BeiGene.
The acceleration of new drug development by artificial intelligence is an inevitable trend. As a rising force in China, DeepIntel will fulfill its mission to “make no new drug difficult to develop and bring hope to patients,” serving as the intelligent infrastructure for global pharmaceutical companies and their service providers. It aims to deliver safer and more effective products to patients worldwide, offering new hope for curing diseases.